|1.||Daly, Robert N: 1 article (01/2003)|
|2.||Sy, Sherwin K B: 1 article (01/2003)|
|3.||Cain, Valerie A: 1 article (01/2003)|
|4.||Simonson, Kristen: 1 article (01/2003)|
|5.||Wright, R Scott: 1 article (01/2003)|
|6.||Williams, Brent: 1 article (01/2003)|
|7.||Wilcox, Racehl A: 1 article (01/2003)|
|8.||Gussak, Ihor: 1 article (01/2003)|
|9.||Pieniaszek, Henry J: 1 article (01/2003)|
|10.||Murphy, Joseph: 1 article (01/2003)|
10/01/1999 - "DMP754 resulted in a significant reduction in thrombus mass and sustained arterial blood flow with 100% prevention of occlusive and nonocclusive thrombosis. "
10/01/1999 - "Additionally, both DMP754 and XV459 (0.1 mg/kg IV or 0.3 to 0.4 mg/kg PO) demonstrated maximal antithrombotic efficacy in preventing electrically induced carotid and coronary artery thrombosis and significant antithrombotic efficacy (P<0.001) at relatively low doses in different settings of arterial thrombosis in the canine model. "
10/01/1999 - "The present study was undertaken to determine intravenous and oral antithrombotic efficacies of DMP754 and XV459 and to compare them with those of other antiplatelet and anticoagulant agents in canine models of arterial thrombosis. "
|3.||Coronary Artery Disease (Coronary Atherosclerosis)
|1.||Platelet Membrane Glycoprotein IIb